RE:RE:RE:2020 - My take Vent patient growth stalled with COVID because co. could not enter hospitals, care facilities to market the home ventilation alternative. Other core activities like oxygen increased, however, and total revenues continued to grow. This does not include COVID related sales.
donmayne wrote: Great response. Thank-you Long-Term 3
Perhaps I should have said "Shelf Registration" not "Shelf Offering". Who knows, they may have a debt offering or a share offering? Probably Casey Hoyt knows and it probably depends on the share price at the time of the offering. He has not disclosed his plan. I have speculated that it will be a share offering if the price returns to $C15 and I speculated that the timing was after the share price peaked.
I should have clarified that I was speaking about growth in terms of the number of active vent patients on recurring billing service at the end of each quarter. This is what I view as their core business because in their presentations, they focus on the opportunity they have in the growing NIV market and their 5% market penetration.
The record shows fabulous growth in active vent patients until Mar 31, 2020 and then shrinkage. This is where I think their growth is on life support. Perhaps they are billing more for each patient, but I am not sure if this qualifies as 'growth'.
5,905 Dec 31, 2018
6,393 Mar 31, 2019
7,130 Jun 30, 2019
7,421 Sep 30, 2019
7,759 Dec 31, 2019
7,965 Mar 31, 2020
7,705 Jun 30, 2020
7,788 Sep 30, 2020
Thanks again for your detailed response.